Market Snapshot

Nasdaq ticker symbol:	IMNN
Stock price (10/4/2024):	$1.08
52-week range:	$0.48- $3.65
Market capitalization:	$15 million

Imunon, Inc. (Nasdaq: IMNN) is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon has two platform technologies: **TheraPlas** modality for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and **PlaCCine** modality for the development of nucleic acid vaccines for infectious diseases.

Strengths: Three ongoing clinical trials spanning two technology platforms, each providing meaningful near-term value drivers. Highly capable staff with global Phase 3 trial experience and vertical integration enabling in-house high yield manufacturing capability, at significant cost savings. Partners at leading academic institutions are progressing clinical assets on time.

Investment Highlights

Highly focused capitalizing on its core competencies and novel technology platform, and its synergies across multiple disease modalities. Technology platforms leverage novel DNA-mediated gene therapy with synthetic delivery systems.

- **Immuno-oncology (TheraPlas)** – High potential asset produces loco-regional IL-12 to recruit the immune system at the tumor site improving outcomes in newly diagnosed ovarian cancer patients. Clinical PoC established with FDA Orphan Drug and Fast Track Designation. Clear potential for development in other cancers with high needs.
  Two ongoing, Phase 2 trials with standard of care neoadjuvant chemotherapy (NACT):
  IL-12 OVATION-2 – Large, randomized trial studying IMNN-001 monotherapy. Top line data showed prolonged median Overall Survival of >11 months compared to the standard of care.
  Positive data supports a Phase 3 registration study. IMNN-001 was well-tolerated with acceptable toxicity profile.
  IL-12 Break Through Cancer Foundation – Randomized trial, largely funded by the Foundation, with IMNN-001 in combination with Avastin. Interim data possible in H2 2024 using primary endpoint minimal disease assessment via second look laparoscopy, a novel means to assess efficacy early. Trial is actively enrolling
- **DNA-based Vaccines (PlaCCine)** - A **partnership opportunity** to develop a first-in-class vaccine platform with potential to address 80+ pathogens, including some with pandemic potential. Technology is "mRNA better" providing advantages in protection durability, safety, speed to market and shelf life at refrigerator temperatures of at least 1 year.
  Phase 1 PoC trial all subjects enrolled; Immunogenicity data readout H2 2024.
- **IMUNON intends to introduce the first immunotherapy for newly diagnosed Ovarian Cancer and meaningly advance the standard of care**. Phase 3 anticipated to initiate in Q1 2025.
  Assuming a 500 patient study, enrollment completion is expected within 3 years and interim and final data within 5 years.

Our Disruptive Non-Viral DNA Technology Platform

Proprietary Synthetic Delivery and Facilitating System, that promote DNA Protection, Uptake, Bioavailability and Enhanced Antigen Expression

Gene Therapy Modality

Delivers DNA Plasmids Coding For Therapeutic Proteins

Multiple Development Plans Ongoing with Positive Phase 2 Data



Vaccine Modality

DNA Plasmid Vectors Engineered for Next Generation Vaccine Technology

Designed for Multiple Antigens with Co-Expression of Immunomodulators

Pipeline of DNA-based Transformative Medicines

Platform	Program	Indication(s)	Discovery	IND enabling	Phase 1	Phase 2	Phase 3
TheraPlas	IL-12 (OVATION 1)	Newly Diagnosed Advanced Ovarian Cancer	IMNN-001		complete		
	IL-12 (OVATION 2)	Newly Diagnosed Advanced Ovarian Cancer	IMNN-001		top line readout July 2024		
	IL-12 IP in combination with **Avastin***	Newly Diagnosed Advanced Ovarian Cancer	IMNN-001		enrolling		
	IL-12 (OVATION 3)	Newly Diagnosed Advanced Ovarian Cancer	IMNN-001			Expected to begin Q1 2025	
PlaCCine	SARS-CoV-2 Clinical Proof-of-Concept	COVID-19 Seasonal Vaccine	IMNN-101				

* Avastin or a biosimilar

IMNN-001: Lead Immuno-Oncology Program

IMNN-001 Modifies the Micro-Environment of Ovarian Cancer

Local production of safe and durable levels of IL-12, a powerful anti-cancer immune agent

- IMNN-001 engineers the peritoneal cavity cells to produce IL-12 physiologically
- Intracavity infusion of IMNN-001 has demonstrated durable and local expression of IL-12 in the peritoneum
- No "cytokine storm" of IL-12 commonly associated with the bolus rIL-12 minimizes excessive systemic exposure of IL-12, thereby giving a favorable safety profile to IMNN-001

Phase 2 OVATION II Trial In Advanced Ovarian Cancer

		Median time to event, Experimental vs Control (months)	Hazard Ratio, Experimental vs Control
Overall Survival (secondary endpoint)	ITT (n=112)	40.5 vs 29.4	0.74 (0.42; 1.30) p=NS
	≥20% of protocol-specified treatments in both arms (n=102)	45.1 vs 29.4	0.64 (0.35; 1.19) p=NS
	PARP-treated patients (n=43)	NE vs 37.1	0.41 (0.13; 1.28) p=NS
Progression-Free Survival (primary endpoint)	ITT (n=112)	14.9 vs 11.9	0.79 (0.51; 1.23) p=NS
	≥20% of protocol-specified treatments in both arms (n=102)	14.6 vs 11.9	0.76 (0.48; 1.22) p=NS
	PARP-treated patients (n=31)	33.8 vs 22.1	0.80 (0.31; 2.12) p=NS

PLACCINE Platform: Powering the Next Generation of Vaccines



Durability of Protection	Durable antigen expression induces robust immunological response
Breadth of Protection	Multicistronic vectors increase the breadth of immune response and allows for combination vaccines
Transmission Advantage	Strong T-cell activity. Option for co-expression of potent immune modifiers increases the immune response and lowers the risk of viral shedding
Safe and Convenient	Synthetic delivery systems present no risk of genotoxicity - no virus, or cytotoxicity - no device. Convenient handling for pandemic control.
Flexible Manufacturing	Truly versatile platform enables rapid response to changing pathogens. Stability and long shelf-life at normal refrigerator temperatures simplifies handling and distribution.

Forward-Looking Milestones

- **IMNN-101 SARS-Co-V-2 Phase 1 results – 2H24**
- **IMNN-001+ bevacizumab Phase 1 interim results – 2H24**
- **IMNN-001 End of Phase 2 meeting – 2H24**
- **IMNN-001 Initiation of Phase 3 (OVATION 3) – 1H25**

Investor Relations Contacts

Imunon
David Gaiero, CFO
dgaiero@imunon.com
(609) 896-9100
www.imunon.com

The information contained herein was obtained from company and other sources believed to be reliable. This does not constitute the solicitation of the purchase or sale of securities. Except for historical information contained herein, matters discussed in this document are forward-looking statements, the accuracy of which is subject to risks and uncertainties. See recent Form 10-K and Forms 10-Q for additional information about the Company and related risks.

October 2024